World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
108643
World Ranking
2637
National Ranking
1477

Overview

Jeffrey S. Weber is affiliated with New York University in the United States and has contributed extensively to the field of medicine, with a primary focus on oncology. Their research spans a range of subfields including molecular biology, immunology, cancer research, and pulmonary and respiratory medicine.

The scientist's recent publications reflect their ongoing work in cancer immunotherapy, particularly in melanoma treatment and immune response. Selected recent papers include:

  • Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study (2024, The Lancet)
  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial (2020, The Lancet Oncology)
  • Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma (2021, Journal of Clinical Oncology)
  • Systemic Therapy for Melanoma: ASCO Guideline (2020, Journal of Clinical Oncology)
  • Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies (2021, Nature Reviews Drug Discovery)

Their frequent coauthors include:

  • Paolo A. Ascierto
  • Georgina V. Long
  • James Larkin
  • Iman Osman
  • Omid Hamid

Geographically and institutionally embedded in the United States, Jeffrey S. Weber has published most prolifically in several key journals:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Clinical Cancer Research
  • Cancer Research
  • Regular and Young Investigator Award Abstracts

The main research topics covered in their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies

Their publications consistently contribute to understanding the mechanisms and treatment options for melanoma and other cancers, often emphasizing immune-based therapies and personalized medicine approaches. The scientist's research outputs are reflected in high citation counts and ongoing collaborations that link clinical oncology, immunotherapy, and translational research.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

    Jeffrey S. Weber;Katharina C. Kähler;Axel Hauschild

  • Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

    Steven A. Rosenberg;James C. Yang;Suzanne L. Topalian;Douglas J. Schwartzentruber

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

    Peter P. Lee;Cassian Yee;Peter A. Savage;Lawrence Fong

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

    Steven A. Rosenberg;John R. Yannelli;James C. Yang;Suzanne L. Topalian

  • Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

    Jeffrey S. Weber;F. Stephen Hodi;Jedd D. Wolchok;Suzanne L. Topalian

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

    Morganna Freeman-Keller;Youngchul Kim;Heather Cronin;Allison Richards

Frequent Co-Authors

Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Caroline Robert
Caroline Robert University of Paris-Saclay
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Adil Daud
Adil Daud University of California, San Francisco
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Vernon K. Sondak
Vernon K. Sondak University of South Florida
Richard F. Kefford
Richard F. Kefford Macquarie University
Mario Sznol
Mario Sznol Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending medical school. There are flexible alternatives to get started or advance in healthcare, especially with today’s online degree options. Many professionals begin as licensed practical nurses. If you’re looking for an entry point, consider enrolling in a lpn program online to fast-track your way into the field.

If you’re already an RN and want to earn your bachelor’s, there are now rn to bsn programs no clinicals, allowing you to further your education from home with minimal on-site requirements.

For nurses aiming for the highest level of clinical practice, accelerated dnp programs can help you earn a doctorate quickly. Additionally, some online dnp programs without dissertation make it more accessible for working nurses to advance without the challenge of lengthy research projects.

Each pathway provides unique opportunities, letting you tailor your medical career to your goals, background, and schedule.

Best Scientists Citing Jeffrey S. Weber

Trending Scientists